Tag: SAFE

In the news release, O Positiv Health Releases Its First Prenatal, PREGGO Prenatal + Probiotic, issued 10-Feb-2026 by O Positiv Health over PR Newswire,...

Featuring Dr. Rhonda Schafer-McLean, a board-certified OB/GYN with more than 15 years of experience caring for women throughout North Dakota

Featuring Dr. Rhonda Schafer-McLean, a board-certified OB/GYN with more than 15 years of experience caring for women throughout North Dakota

Amsterdam, June 10, 2026

JERICHO, N.Y., June 10, 2026 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM) today announced that its operating subsidiary, Kimco Realty OP, LLC (“Kimco OP”), intends to offer, subject to market and other conditions, $500,000,000 aggregate principal amount of exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Kimco Realty Corporation (“Kimco”) will fully and unconditionally guarantee the notes on a senior, unsecured basis. Kimco OP also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $75,000,000 aggregate principal amount of notes.

Continues to advance the project and is working directly with the hyperscaler customer

Continues to advance the project and is working directly with the hyperscaler customer

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases,...

Trading to begin at market open on Monday, June 15, 2026TORONTO, June 10, 2026 /CNW/ - Hemlo Mining Corp. (TSXV: HMMC) (OTCQX: HMMCF) (the...

Technology / E-Motion™ Platform IntelligenceVision Marine is extending a key display supply and integration relationship through 2029, supporting the connected digital interface of its...

The withdrawal does not reflect any change in the Company's business outlook, operating strategy, or confidence in the value of its assetsDALLAS, June 10,...

WeRide outlined plans to commercialize its L4 AV portfolio in Slovakia during a meeting with His Excellency Mr. Robert Fico Prime Minister of Slovakia.

AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced the pricing of its previously announced a public offering of 10,879,376 shares of its common stock at a public offering price per share of $4.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 7,870,624 shares of its common stock at a public offering price of $3.9999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately. The aggregate gross proceeds to Shattuck from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses payable by Shattuck, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 11, 2026, subject to the satisfaction of customary closing conditions. In addition, Shattuck has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.